• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Tempest Therapeutics, Inc. - Common Stock (NQ:TPST)

    2.650 +0.100 (+3.92%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Tempest Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
    $4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrants 
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Tempest Therapeutics Stock Plummets Nearly 50% Amid Shareholder Dilution Fears Following CAR-T Acquisition
    San Francisco, CA – November 19, 2025 – Tempest Therapeutics, Inc. (NASDAQ: TPST) saw its stock price plummet by a staggering 48.92% today, wiping out nearly half of its market value in a single... 
    Via MarketMinute
    News headline image
    Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
    $4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrants 
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction ↗
    The transaction is expected to close in early 2026, provided it receives all required approvals. 
    Via Stocktwits
    News headline image
    Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Nasdaq Gains Over 100 Points; Target Trims Earnings Forecast ↗
     
    Via Benzinga
    News headline image
    Why Tempest Therapeutics (TPST) Stock Is Down 45% Today ↗
    Tempest Therapeutics shares fell Wednesday after the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience. 
    Via Benzinga
    News headline image
    Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Thursday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
    Via Chartmill
    News headline image
    Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    Get insights into the top gainers and losers of Monday's pre-market session. ↗
    As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success ↗
    Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program. 
    Via Benzinga
    News headline image
    Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger ↗
    CEO Stephen Brady emphasized the company's strong data and regulatory momentum, pointing to Phase 2 results for amezalpat in advanced liver cancer and FDA clearance for a pivotal Phase 3 study. 
    Via Stocktwits
    Topics World Trade
    News headline image
    Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Monday's session: gap up and gap down stocks ↗
    Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
    Via Chartmill
    News headline image
    Tempest Reports Year End 2024 Financial Results and Provides Business Update
    From Tempest Therapeutics
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.